David A. Siegel Uro Gen Pharma Ltd. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 24,900 shares of URGN stock, worth $316,230. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,900
Previous 18,800
32.45%
Holding current value
$316,230
Previous $282,000
47.87%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding URGN
# of Institutions
119Shares Held
39.3MCall Options Held
158KPut Options Held
161K-
Rtw Investments, LP New York, NY3.56MShares$45.2 Million1.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.3MShares$41.9 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.08MShares$39.2 Million0.78% of portfolio
-
Great Point Partners LLC Greenwich, CT2.91MShares$36.9 Million12.93% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.45MShares$31.1 Million0.11% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $289M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...